IRIS UniCatt

Galli, Eugenio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.070
EU - Europa 2.025
NA - Nord America 1.994
SA - Sud America 395
AF - Africa 53
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.540
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.914
SG - Singapore 918
CN - Cina 465
DE - Germania 377
NL - Olanda 358
IT - Italia 349
BR - Brasile 326
VN - Vietnam 249
SE - Svezia 178
FI - Finlandia 171
FR - Francia 170
PL - Polonia 151
IN - India 101
GB - Regno Unito 72
JP - Giappone 71
ID - Indonesia 45
IE - Irlanda 45
CA - Canada 40
KR - Corea 38
HK - Hong Kong 36
RU - Federazione Russa 31
MX - Messico 28
AT - Austria 24
CZ - Repubblica Ceca 23
BD - Bangladesh 22
AR - Argentina 21
ES - Italia 19
IQ - Iraq 18
SA - Arabia Saudita 17
TR - Turchia 16
BE - Belgio 14
CO - Colombia 12
EC - Ecuador 12
UZ - Uzbekistan 11
ZA - Sudafrica 11
VE - Venezuela 10
CI - Costa d'Avorio 9
MA - Marocco 9
UA - Ucraina 9
IL - Israele 7
KE - Kenya 7
LT - Lituania 7
PK - Pakistan 6
IR - Iran 5
JO - Giordania 5
UY - Uruguay 5
AZ - Azerbaigian 4
KZ - Kazakistan 4
LB - Libano 4
NP - Nepal 4
TN - Tunisia 4
BO - Bolivia 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
GR - Grecia 3
KG - Kirghizistan 3
KW - Kuwait 3
OM - Oman 3
PH - Filippine 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AU - Australia 2
BG - Bulgaria 2
CL - Cile 2
EG - Egitto 2
GY - Guiana 2
HR - Croazia 2
HU - Ungheria 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
PR - Porto Rico 2
PY - Paraguay 2
QA - Qatar 2
SN - Senegal 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
CH - Svizzera 1
CR - Costa Rica 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 6.539
Salva come PNG Salva come JPEG
Città #
Singapore 522
Amsterdam 348
San Jose 301
Ashburn 193
Munich 155
Frankfurt am Main 149
Warsaw 144
Chandler 129
Rome 124
Hefei 105
Helsinki 103
Beijing 89
Los Angeles 76
The Dalles 74
St Louis 73
Tokyo 70
Hanoi 69
Ho Chi Minh City 66
Lauterbourg 66
New York 61
Chicago 58
Milan 58
Hyderabad 57
Council Bluffs 52
Dublin 41
Seoul 38
Jakarta 36
Florence 35
Dallas 34
Santa Clara 34
Hong Kong 33
Kent 33
Lappeenranta 33
Fairfield 31
Turku 27
London 23
São Paulo 21
Paris 20
Seattle 20
Nuremberg 19
Orem 19
Brooklyn 18
Montreal 16
Brno 15
Chennai 15
Da Nang 15
Moscow 15
Bremen 14
Brussels 14
Wilmington 14
Boston 13
Buffalo 13
Düsseldorf 13
Houston 13
Marseille 13
Toronto 13
Woodbridge 13
Belo Horizonte 12
Princeton 12
Atlanta 11
Tashkent 11
Vienna 11
Manchester 10
Mexico City 10
Rio de Janeiro 10
San Mateo 10
Abidjan 9
Campinas 9
Denver 9
Haiphong 9
Phoenix 9
Poplar 9
Redmond 9
Stockholm 9
Charlotte 8
Falls Church 8
Guangzhou 8
Johannesburg 8
Miami 8
Baghdad 7
Shanghai 7
Tampa 7
Bogotá 6
Cambridge 6
Caracas 6
Casablanca 6
Cattolica 6
Curitiba 6
Jeddah 6
Nairobi 6
New Delhi 6
Portsmouth 6
Riyadh 6
Biên Hòa 5
Brasília 5
Columbus 5
Dhaka 5
Falkenstein 5
Governador Valadares 5
Madrid 5
Totale 4.197
Salva come PNG Salva come JPEG
Nome #
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 586
Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients 290
PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma 284
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma 230
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 147
PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma 144
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 143
Comorbidity assessment to determine prognosis in older adult patients with classical Hodgkin lymphoma 138
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 136
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity 125
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 123
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 119
Burkitt lymphoma as fourth neoplasia in a patient affected by cowden syndrome with a novel PTEN germline pathogenic variant 119
Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study 116
Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management 115
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation 113
COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: what is the role of anti-CD20 antibody? 110
Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (ddPCR) 109
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy 108
Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis 106
CAR-T treatment is safe and effective in adult patients with Down syndrome and B-cell acute lymphoblastic leukemia (B-ALL) 106
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study 105
CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation 105
Haploidentical bone marrow transplantation for AML in remission following TBF conditioning: a long-term follow up 105
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-t Cells 102
Coagulopathy in CAR-T: Critical concern or mere blip? 101
The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity 101
Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath? 101
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 100
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. 99
What is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome? 99
Treatment options for elderly/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: A comprehensive review 98
Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic 95
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 89
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management 88
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 88
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 86
Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T) 85
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies 83
G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma 82
The impact of donor-specific antibodies’ presence on the outcome post-allogeneic hematopoietic stem cell transplantation: a survey from a single center 80
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience 79
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT 79
Prognostic factors in hodgkin lymphoma 79
Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma 77
Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant 74
Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience 73
Vascular inflammation in patients undergoing anti-CD19 chimeric antigen receptor-T cells for haematologic malignancies: a call for cardiovascular surveillance 72
VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation 68
Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia 67
Spontaneous resolution of “therapy-related myelodysplasia” occurred after treatment with CAR-T cells: All that glitters is not gold 65
Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review 64
Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant 62
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma 58
Predicting therapy-related myeloid neoplasms after CAR-T with the Clonal Haematopoiesis Risk Score (CHRS) 53
Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)? 48
Frail is not fail: Limited impact of comorbidities on non-relapse mortality and safety in patients with LBCL treated with CAR-T 45
Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study 42
Predictors of Neurotoxicity in a Large Cohort of Italian Patients Undergoing Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy 39
Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study 37
Frail is not fail: Limited impact of comorbidities on non‐relapse mortality and safety in patients with LBCL treated with CAR‐T 37
Predictors of Neurotoxicity in a Large Cohort of Italian Patients Undergoing Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy 31
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 29
Cinnamon-enriched chocolate pralines as a delivery system for Lacticaseibacillus rhamnosus CRL1505: viability and digestive stability 27
Totale 6.664
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.441
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.441
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202118 0 0 0 0 0 0 0 0 0 0 12 6
2021/2022135 9 5 5 5 14 8 3 14 6 6 27 33
2022/2023450 74 51 17 68 30 54 35 27 48 21 23 2
2023/2024412 10 72 28 42 6 52 30 38 7 34 34 59
2024/20251.795 40 30 79 172 119 96 124 79 190 172 418 276
2025/20263.568 421 139 219 327 466 650 560 202 270 308 6 0
Totale 6.664